Please login to the form below

situximab

This page shows the latest situximab news and features for those working in and with pharma, biotech and healthcare.

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

Latest news

Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Executive/ Senior Account Executive: competitive Salary Offfered

Principal Health Economist - North-West: Negotiable

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Associate Medical Director: Excellent PTO, bonus and 401k package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Senior Editorial Assistant – Greater Manchester: DOE

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Director: Competitive Salary Offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Account Manager / Account Director: Competative

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Editorial Manager - MedComms: DOE

Account Manager: Negotiable

Account Manager- Healthcare Advertising: Negotiable

Business Development Director – Health Education: excellent commission

Client Services Director – Medical Education Agency – North West...: Salary TBC

Associate Director: £75, 000-90, 000

Systematic Reviewer - Oxford: Negotiable

Account Manager- Healthcare Advertising: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...